6D-MRI for Pancreatic Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Pancreatic Cancer6D-MRI - DiagnosticTest
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if 6D-MRI can help predict outcomes for pancreatic cancer patients.

Eligible Conditions
  • Pancreatic Cancer

Treatment Effectiveness

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: 2 years

2 years
Number of participants with R0 resection
Rate of progression-free survival from baseline
Baseline, 2 years
Change in functional status from baseline, as measured by the Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status
Change in overall health from baseline, as measured by the Charlson Comorbidity Index (CCI)

Trial Safety

Trial Design

1 Treatment Group

6D-MRI
1 of 1

Experimental Treatment

36 Total Participants · 1 Treatment Group

Primary Treatment: 6D-MRI · No Placebo Group · N/A

6D-MRI
DiagnosticTest
Experimental Group · 1 Intervention: 6D-MRI · Intervention Types: DiagnosticTest

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Cedars-Sinai Medical CenterLead Sponsor
456 Previous Clinical Trials
154,199 Total Patients Enrolled
Stephen Pandol, MDPrincipal Investigator - Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
1 Previous Clinical Trials
24 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have access to a device that can sync to the Fitbit.